News >

Cirmtuzumab/Ibrutinib Study Expands to Include Patients With MCL

Nichole Tucker
Published: Thursday, Nov 07, 2019

Hun Ju Lee, MD, associate professor of medicine, Department of Lymphoma & Myeloma, University of Texas MD Anderson Cancer Center

Hun Ju Lee, MD

The phase I/II CIRLL study (NCT03088878), which is evaluating the combination of the monoclonal antibody cirmtuzumab (UC-961) and ibrutinib (Imbruvica), has opened an expansion cohort to include patients with mantle cell lymphoma (MCL).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication